EUCTR2006-005127-42-DE进行中（未招募）不适用
Effect of Prandial Treatment with Insulin Glulisine compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients - Insulin glulisine and postprandial vascular function
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Type 2 Diabetes mellitus according to ADA criteria
- •2. HbA1c between 6.5 % and 9.9 %
- •3. Monotherapy with sulfonylurea or combined with Metformin in a stable dosage within the last 3 months
- •4. Age between 40 and 70 years
- •5. BMI < 40
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Type 1 Diabetes mellitus
- •2. Pre-Treatment with insulin within the last 6 months prior to screening
- •3. Treatment with glitazones within the last 6 months prior to screening
- •4. Pre-Treatment with PPARy-agonists, glinids or glucosidase inhibitors within the last 4 weeks prior to screening
- •5. Untreated hypertension stage II-III according to WHO criteria
- •6. Planned or anticipated change in antidiabetic and/or concomitant medication during study participation
- •7. Total Cholesterol > 300 mg/dl (anamnestically)
- •8. Hypocalemia (K < 3.5 mmol/l)
- •9. Major micro- or macrovascular complications as judged by the investigator
- •10. Tobacco use within the last 12 months prior to screening
- •11. Drugs with major impact on endothelial function like nitrates etc.
- •12. History of drug or alcohol abuse within the last five years prior to screening
- •13. Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- •14. History of severe or multiple allergies
- •15. Treatment with any other investigational drug within 3 months prior to screening
- •16. Progressive fatal disease
- •17. History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.1 mg/dL in women and > 1.5 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator
- •18. Pregnancy or breast feeding
- •19. Sexually active women of childbearing potential not consistently and correctly practicing birth control by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
- •20. Lack of compliance or other similar reason, that according to investigator, precludes satisfactory participation in the study
研究者
相似试验
进行中（未招募）
不适用
Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patientsMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2008-001184-11-DEBiodel Inc
进行中（未招募）
不适用
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump StudyType I Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-003579-38-ATsanofi-aventis groupe270
进行中（未招募）
不适用
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump StudyType I Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-003579-38-NLsanofi-aventis groupe270
进行中（未招募）
不适用
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump StudyType I Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-003579-38-GBsanofi-aventis groupe270
进行中（未招募）
1 期
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump StudyType I Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2007-003579-38-FRsanofi-aventis groupe270